Dogecoin Cash, Inc. (DOGP)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 2 | 2 | 1 | 1 | 1 | 1 | - |
| Operating profit | $m | -1 | -1 | ||||||
| Net profit | $m | -2 | -2 | -1 | -1 | -2 | -1 | -1 | - |
| EPS reported | $ | -0.00 | -0.00 | ||||||
| Operating cashflow per share | $ | -0.00 | -0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.00 | -0.00 | ||||||
| Free cash flow | $m | -0 | -0 | ||||||
| Net debt | $m | -1 | -0 | ||||||
| Book value equity | $m | -2 | -2 | ||||||
| Book value per share | $ | -0.01 | -0.01 | ||||||
| Number of shares | m | 150.81 | 162.19 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 0.11 | ||||||
| P/B LTM | x | -1.38 | -1.20 | ||||||
| P/S LTM | x | 3.49 | 3.57 | ||||||
| P/FCF LTM | x | -65.15 | -38.54 | ||||||
| EV/EBITDA LTM | x | -0.30 | -1.04 | ||||||
| EV/Sales LTM | x | 4.04 | 2.25 | ||||||
| Earnings Yield LTM | % | -22.23% | +909.09% | ||||||
| FCF Yield | % | -1.53% | -2.60% | ||||||
| Quality | |||||||||
| ROE | % | +30.69% | +29.78% | ||||||
| ROIC | % | -30.04% | -30.81% | ||||||
| Operating margin | % | -73.99% | -73.72% | ||||||
| Gross margin | % | +64.04% | +55.15% | ||||||
| FCF/Sales | % | -5.36% | -9.28% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -7.95% | -10.13% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.09 | -0.14 | ||||||
| Net Debt/EBITDA | x | -0.04 | -0.16 | ||||||
| EBIT/Net interest | x | -5.88 | -5.37 | ||||||
| Net debt/market cap | % | +16.79% | +39.47% | ||||||
| Net debt/Equity | x | 0.27 | 0.20 | ||||||
| Gross debt/equity | x | -0.23 | -0.22 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Dogecoin Cash, Inc., through its various divisions, offers online telemedicine referral services, enabling clients across the United States to obtain medical marijuana cards. A central offering is PrestoDoctor, a digital healthcare platform that facilitates virtual connections between individuals and licensed physicians via video conferencing for securing medical cannabis recommendations. Beyond its telehealth operations, the company is engaged in the creation of several product lines. These encompass lozenges crafted for relief, "Recover" — a potent, deeply penetrating therapeutic balm designed to ease discomfort in sore muscles, joints, and conditions like arthritis or back pain — and "Trauma Cream," a topical solution infused with a blend of cannabinoids and THC. Furthermore, Dogecoin Cash, Inc. intends to introduce high-end men's and women's fashion from various suppliers through its e-commerce site, www.cbds.com. The firm also holds intellectual property licenses pertaining to the production of medical cannabis edibles. Its business endeavors primarily target both the cannabidiol (CBD) and broader cannabis sectors. The entity, previously known as Cannabis Sativa, Inc., adopted the name Dogecoin Cash, Inc. in November 2024 and is headquartered in Mesquite, Nevada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Dogecoin Cash, Inc., through its various divisions, offers online telemedicine referral services, enabling clients across the United States to obtain medical marijuana cards. A central offering is PrestoDoctor, a digital healthcare platform that facilitates virtual connections between individuals and licensed physicians via video conferencing for securing medical cannabis recommendations. Beyond its telehealth operations, the company is engaged in the creation of several product lines. These encompass lozenges crafted for relief, "Recover" — a potent, deeply penetrating therapeutic balm designed to ease discomfort in sore muscles, joints, and conditions like arthritis or back pain — and "Trauma Cream," a topical solution infused with a blend of cannabinoids and THC. Furthermore, Dogecoin Cash, Inc. intends to introduce high-end men's and women's fashion from various suppliers through its e-commerce site, www.cbds.com. The firm also holds intellectual property licenses pertaining to the production of medical cannabis edibles. Its business endeavors primarily target both the cannabidiol (CBD) and broader cannabis sectors. The entity, previously known as Cannabis Sativa, Inc., adopted the name Dogecoin Cash, Inc. in November 2024 and is headquartered in Mesquite, Nevada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free